［1］RICHA DAWAR,FRANCISCO HERNANDEZ-ILIZALITURRI.The emerging role of lenalidomidein themanagement of mantle cell lymphoma (MCL)［J］.Best Pract Res Clin Haematol,2012,25(2):185-190.
[2]CAMPO E,RULE S.Mantle cell lymphoma:evolving management strategie［J］.Blood,2015,125:48-55.
[3]CORTELAZZO S,PONZONI M,FERRERI AJ,et al.Mantle cell lymphoma ［J］.Crit Rev Oncol Hematoal,2012,82(1):78-101.
[4]刘耀,张曦.套细胞淋巴瘤的治疗现状及进展［J］.临床荟萃,2014,29(10):1140-1146.
LIU Y,ZHANG X.Treatment and advance in mantle cell lymphoma［J］.Clinical Collection,2014,29(10):1140-1146.
[5]谢彦，朱军．套细胞淋巴瘤诊断与治疗中国专家共识（2016版）解读［J］．临床血液学杂志，2017,30(9):683-686.
XIE Y,ZHU J.The interpretation of the Chinese expert consensus to mantle cell lymphoma(2016 edition) ［J］.Journal of Clinical Hematology,2017,30(9):683-686.
[6]WILLIAMS ME,DREYLING M,WINTER J,et al.Management of mantle cell lymphoma:key challenges and next steps ［J］.Clin Lymphoma Myeloma Leuk,2010,10:336-346.
[7]DREYLING M,THIEBLEMONT C,GALLAMINI A,et al.ESMO consensus conferences:guidelines on malignant lymphoma.Part 2:marginal zone lymphoma,mantle cell lymphoma,peripheral T-cell lymphoma［J］.Ann Oncol,2013,24:857-877.
[8]RUAN J，MARTIN P，SHAH B，et al．Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma［J］．N Engl J Med，2015,373(19):1835-1844．
[9]LENZ G，DREYLING M，HOSTER E，et al．Immunochemotherapy with rituximab and cyclophosphamide，doxorubicin，vincristine，and prednisone significantly improves response and time to treatment fail［J］．J Clin Oncol，2005，23(9):1984-1992．
[10]REDDY N，DEEB G，ROTH M，et al．Immunomodulatory drugs stimulate natural killer cell function，alter cytokine production by dendritic cells，and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo ［J］．Br J Haematol，2008，140(1):36-45．
[11]LUO J，GAGNE JJ，LANDON J，et al．Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America:A population-based cohort study［J］．Eur J Cancer，2017,70:22-33．
[12]LISTER TA，CROWTHER D，SUTCLIFFE SB，et al．Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin' s disease:Cotswolds meeting［J］．J Clin Oncol，1989，7(11):1630-1636．
[13]CHESON BD，PFISTNER B，JUWEID ME，et al．Revised response criteria for malignant lymphoma［J］．J Clin Oncol，2007，25(5):579-586．
[14]冯艺，周宇红．利妥昔单抗联合CHOP化疗方案治疗B细胞非霍奇金淋巴瘤感染病例观察［J］．中国临床医学，2010，17(6):889-891.
FENG Y,ZHOU YH.The observation study of infection cases occurred during rituximab in combination with CHOP chemotherapy for B cell non-Hodgkin's lymphoma［J］.Chinese Journal of Clinical Medicine,2010,17 (6):889-891.
[15]陆卫华.利妥昔单抗联合CHOP治疗弥漫型大B细胞淋巴瘤效果观察［J］．临床合理用药,2019,12(2A):24-25.
LU WH.Effect observation of rituximab combined with CHOP in treatment of diffuse large B-cell lymphoma ［J］.Clinically Reasonable Medication,2019,12(2A):24-25.
[16] KAUFMANN H，RADERER M，W HRER S，et al．Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma［J］．Blood，2004，104(8):2269-2271．
[17]SKARBNIK AP，GOY AH．Lenalidomide for mantle cell lymphoma［J］．Expert Rev Hematol，2015,8(3):257-264．
[18]RAMSAY AG，CLEAR AJ，KELLY G，et al．Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide:implications for the tumor microenvironment and immunotherapy［J］．Blood，2009，114(21):4713-4720．
[19]WITZIG TE，WIERNIK PH，MOORE T，et al．Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin' s lymphoma［J］．J Clin Oncol，2009，27(32):5404-5409．
[20]ZAJA F,DE LUCA S,VITOLO U,et al.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma:clinical results and effects on microenvironment and neo-angiogenic biomarkers［J］.Haematologica,2012，97:416-422.
[21]王晓平，李晖，吉晓春，等.雷利度胺联合利妥昔单抗治疗复发性滤泡性淋巴瘤的疗效［J］．广东医学,2017,38(21):3350-3356.
WANG XP,LI H,JI XC,et al.Efficacy analysis of lenalidomide combined with rituximab in recurrent follicular lymphoma ［J］.Guangdong Medicine,2017,38(21):3350-3356.